IQWiG finds no additional Eylea benefit in DME

The German Institute for Quality and Efficiency in Health Care (IQWiG) said in a dossier assessment that an added benefit was not proven for Eylea aflibercept from Bayer AG (Xetra:BAYN) for visual impairment due to diabetic macular edema (DME).

IQWiG compared Eylea indirectly with Lucentis ranibizumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) in patients whose fovea centralis was affected by the edema, using data from trials in which each drug was tested against laser photocoagulation. IQWiG said the data showed no statistically significant differences between the Eylea and Lucentis groups in visual acuity, side effects or quality of life. ...